Segment Information (Tables)

9 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended December 31,								Nine Months Ended December 31,
	2022				2021				2022				2021
	(In thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C (1)	$	14,680	22	%	$	9,676	17	%	$	41,365	20	%	$	33,123	19	%
Customer B (2)	$	13,068	20	%	$	8,069	14	%	$	36,258	18	%	$	29,281	17	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the U.K.

Schedule Of Company Revenue and Adjusted EBITDA by Segment

he Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended December 31,						Nine Months Ended December 31,
	2022			2021			2022			2021
	(In thousands)
Segment Revenue:
Consumer and Research Services	$	66,940		$	56,891		$	207,112		$	171,334
Total revenue (1)	$	66,940		$	56,891		$	207,112		$	171,334
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(8,313	)	$	(31,967	)	$	(22,986	)	$	(33,232	)
Therapeutics Adjusted EBITDA		(21,471	)		(19,916	)		(58,599	)		(57,046	)
Unallocated Corporate		(13,488	)		(12,129	)		(41,057	)		(30,692	)
Total Adjusted EBITDA	$	(43,272	)	$	(64,012	)	$	(122,642	)	$	(120,970	)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(91,961	)	$	(89,396	)	$	(247,558	)	$	(147,946	)
Adjustments
Interest (income) expense, net		(3,671	)		(76	)		(5,307	)		(213	)
Other (income) expense, net		(855	)		(22	)		267			(39	)
Change in fair value of warrant liabilities		—			(3,695	)		—			(32,989	)
Income tax benefit		(613	)		(3,512	)		(2,139	)		(3,512	)
Depreciation and amortization		5,257			4,681			15,512			14,188
Amortization of acquired intangible assets		4,265			2,898			12,847			2,898
Impairment of acquired intangible assets		9,968			—			9,968			—
Stock-based compensation expense		34,338			17,409			93,768			37,473
Acquisition-related costs (2)		—			7,701			—			9,170
Total Adjusted EBITDA	$	(43,272	)	$	(64,012	)	$	(122,642	)	$	(120,970	)

(1)There was no Therapeutics revenue for the three and nine months ended December 31, 2022 and 2021.

(2)For the three and nine months ended December 31, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees.